VERO
Venus Concept Inc.2.2600
+0.5900+35.3%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
4.20MP/E (TTM)
-Basic EPS (TTM)
-45.26Dividend Yield
0%Recent Filings
8-K
Lender consents extend runway
Venus Concept secured lender consents on January 29, 2026, waiving MSLP and Bridge Loan liquidity covenants through February 13 while extending Bridge maturity from January 31 to February 13 and PIK-ing February 8 interest into principal. Lenders funded the seventeenth $2M Bridge drawdown for working capital. Short-term liquidity breather granted.
8-K
Delists Nasdaq, extends loans
Venus Concept secured lender consents on January 14, 2026, waiving minimum liquidity covenants through January 31 while extending its Bridge Loan maturity to that date. Board approved voluntary Nasdaq delisting via Form 25 around January 30, effective February 6, followed by Form 15 to suspend SEC filings. Costs crushed public burdens. Delisting eyes annual savings amid low volumes.
8-K
Lender consents extend deadlines
Venus Concept secured lender consents on December 31, 2025, waiving minimum liquidity covenants through January 14, 2026, under both its $50M MSLP loan and $2.2M+ Bridge loan. Bridge loan maturity extended to January 14; January 8 interest payment on MSLP switches to PIK, adding to principal. Lenders extract full releases. Short-term breathing room granted.
8-K
Lender consents extend runway
Venus Concept secured lender consents on November 30, 2025, waiving minimum liquidity covenants through year-end and allowing PIK interest on its $50M MSLP loan while extending its $28M bridge loan maturity to December 31. Lenders funded a $1.5M fourteenth drawdown on November 25 for working capital. Liquidity relief buys time, yet debt piles higher.
8-K
FDA clears Venus NOVA
Venus Concept secured FDA 510(k) clearance for Venus NOVA on November 10, 2025, its advanced multi-application platform for non-invasive body, face, and skin treatments, with U.S. launch set for December. Q3 revenue fell 8% to $13.8M amid hair business sale delays, yet EBD systems sales stabilized at $9.6M, up 2% YoY. Debt dropped 24% to $30.1M via conversions. Venus NOVA launches soon.
AIRS
AirSculpt Technologies, Inc.
2.57-0.06
BVS
Bioventus Inc.
7.52+0.02
CERS
Cerus Corporation
2.16+0.15
CNMD
CONMED Corporation
39.20-1.12
EMED
Electromedical Technologies, In
0.00+0.00
INMD
InMode Ltd.
14.48+0.15
NVNO
enVVeno Medical Corporation
0.32+0.01
SNWV
SANUWAVE Health, Inc.
31.46-0.18
TMCI
Treace Medical Concepts, Inc.
2.70-0.07
VVOS
Vivos Therapeutics, Inc.
2.02+0.00